1. IL-12 and IL-23

3. Introduction

4. IL-23/T17-Mediated Effects on Epidermal Keratinocytes in Psoriatic Disease

5. Role of IL-23/IL-17 Axis in Driving Enthesitis

6. Role of IL-12 and IL-23 in Chronic Intestinal Inflammation

7. Genetic and Pathophysiology Overlap of Spondyloarthropathies and Related Conditions

8. Clinical Overlap Between Immunoinflammatory Disorders of Skin, Joints, and Gut

9. Therapeutic Approaches

10. Key Clinical Data in Psoriasis

11. Key Clinical Data in Psoriasis (Cont)

12. Role of Selective IL-23 p19 Targeting

13. Key Clinical Data in PsA

14. Key Clinical Data in Crohn Disease

15. Role of Real-World Data vs Randomized Clinical Trials

16. Drug Survival and Safety of Ustekinumab From Psoriasis Real-World Data

17. Drug Survival From Psoriasis Real-World Data

18. Drug Survival From Psoriasis Real-World Data (Cont)

19. Drug Survival From Psoriasis Real-World Data (Cont)

20. Drug Survival From Psoriasis Real-World Data (Cont)

21. Drug Survival From PsA Real-World Data

22. Management of Patients With Immune-Mediated Inflammatory Diseases

23. Management of Patients With Immune-Mediated Inflammatory Diseases (cont)

24. Future Biologics Targeting IL-23

25. Conclusions

26. Abbreviations

27. Abbreviations (cont)